GnRH agonist in association with hCG versus hCG alone for final oocyte maturation triggering in GnRH antagonist cycles

What Was Tested

This randomized controlled trial looks at hCG (human chorionic gonadotropin).

To analyze gonadotropin-releasing hormone (GnRH) agonist in association with human chorionic gonadotropin (hCG) (dual triggering) versus hCG alone (conventional triggering) for final oocyte maturation triggering in GnRH antagonist cycles in an unselected population of Brazilian women.

Who Took Part

The abstract describes 114 patients taking part.

PubMed tags the participants as women only.

This prospective case-control study involved 114 patients referred to autologous in vitro fertilization treatment between February 2018 and August 2019, recruited regardless of age, infertility factor or number of cycles.

The patients were randomly allocated into two groups according to oocyte maturation triggering approach: group A (n = 48) - hCG only; and group B (n = 66) - hCG plus GnRH agonist.

How the Study Was Run

In design terms this was a randomized study.

Because people in this hCG (human chorionic gonadotropin) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The main outcomes measured were the number of total and metaphase II (MII) oocytes retrieved.

What Was Measured

The subject headings attached to it are Case-Control Studies, Chorionic Gonadotropin, Fertilization in Vitro, Gonadotropin-Releasing Hormone, Oocytes and Ovulation Induction.

Author keywords: GnRH agonist, GnRH antagonist, dual triggering and human chorionic gonadotropin.

What This Means in Plain Language

The paper is a randomized study of hCG (human chorionic gonadotropin) in 114 patients.

The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (JBRA assisted reproduction), a journal based in Brazil.

More context: the hCG (human chorionic gonadotropin) compound page, all human trials.